Drug Trial Radar · NCT04565015
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 21, 2020
Primary completion
May 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- GC Biopharma CorpIndustry
- Sponsor type
- Industry
- Collaborators
- Atlantic Research Group
- First posted
- Sep 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).
Conditions
- Primary Immune Deficiency
Interventions
GC5107Biological
Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Pharmacokinetic (PK) Plasma concentration-time curve of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
- The Pharmacokinetic (PK) Half-life of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
- The Pharmacokinetic (PK) Area under the curve of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
- The Pharmacokinetic (PK) Volume of distribution of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
- The Pharmacokinetic (PK) Maximum concentration of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
- The Pharmacokinetic (PK) Minimum concentration of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
- The Pharmacokinetic (PK) Time of maximum concentration of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
- The Pharmacokinetic (PK) Clearance of total IgGTime frame: before and after 5th infusion (12 or 16 weeks)
- Trough serum total IgG levels before each infusion of GC5107 in all subjects and the interval between infusionsTime frame: 12 months
- The proportion of infusions with temporally associated adverse events (AEs) that occur during or within 1 hour, 24 hours, and 72 hours following an infusion of investigational productTime frame: 12 months
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
Immunoe Health & Research Centers
Centennial, Colorado
Allergy Partners of North Texas Research
Dallas, Texas
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Fairfax, Virginia
Children's Hospital of Richmond at VCU
Richmond, Virginia
University Clinical Center Sarajevo
Sarajevo, Sarajevo, Bosnia and Herzegovina
University clinical center Tuzla
Tuzla, Tuzla, Bosnia and Herzegovina
Institute for Child and Youth Health Care of Vojvodina
Novi Sad, Novi Sad, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.